Contribution of IL-33 to the Pathogenesis of Colorectal Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2018 Dec 15

PMID 30547011

Citations 16

Authors

Guanglin Cui

Aping Yuan

Zhigang Pang

Wei Zheng

Zhenfeng Li

Rasmus Goll

Affiliations

Soon will be listed here.

Abstract

The development of colorectal cancer (CRC) is not only determined by transformed cells , but also by factors existing in their immune microenvironment. Accumulating scientific evidence has revealed that interleukin (IL)-33, an IL-1 family member, plays an essential role in the regulation of immune response and is relevant in CRC pathogenesis. Data from both human and experimental studies demonstrated that IL-33 inhibits host anti-tumor immunity, remodels tumor stroma and enhances angiogenesis, thereby promoting the development of CRC. These pro-tumor effects of IL-33 are mainly mediated by IL-33 receptor ST2 (also known as IL-1RL1). Based on those findings, it is currently hypothesized that the IL-33/ST2 pathway is a potential biomarker and therapeutic target for colorectal tumorigenesis. Herein, we summarize the recent discoveries in understanding the critical role of the IL-33/ST2 pathway in contributing to the pathogenesis of colorectal tumorigenesis and discuss its potential implications for the future development of effective anti-tumor strategies.

Citing Articles

Association of Microsatellite Instability and Gene Expression Profile in Colorectal Carcinoma and Potential Implications for Therapy.

Kibriya M, Jasmine F, Khamkevych Y, Raza M, Kamal M, Bissonnette M Medicina (Kaunas). 2024; 60(3).

PMID: 38541076 PMC: 10972457. DOI: 10.3390/medicina60030348.

IL-33 aggravates extranodal NK/T cell lymphoma aggressiveness and angiogenesis by activating the Wnt/β-catenin signaling pathway.

Ni M, Wang Y, Yang J, Ma Q, Pan W, Li Y Mol Cell Biochem. 2024; 480(1):265-278.

PMID: 38443748 DOI: 10.1007/s11010-024-04944-y.

Colorectal Cancer in Correlation With Clinicopathological Variables: The Effects of Hypoxia-Inducible Factor-1 Alfa or the InterLeukin-33 and Vascular Endothelial Growth Factor?.

Ahmed H, Ilias M Cureus. 2024; 16(1):e51658.

PMID: 38313904 PMC: 10838115. DOI: 10.7759/cureus.51658.

cross-talk between metastasis-competent circulating tumor cells and platelets in colon cancer: a malicious association during the harsh journey in the blood.

Eslami-S Z, Cortes-Hernandez L, Glogovitis I, Antunes-Ferreira M, DAmbrosi S, Kurma K Front Cell Dev Biol. 2023; 11:1209846.

PMID: 37601099 PMC: 10433913. DOI: 10.3389/fcell.2023.1209846.

Cytokine-mediated crosstalk between cancer stem cells and their inflammatory niche from the colorectal precancerous adenoma stage to the cancerous stage: Mechanisms and clinical implications.

Cui G, Wang Z, Liu H, Pang Z Front Immunol. 2022; 13:1057181.

PMID: 36466926 PMC: 9714270. DOI: 10.3389/fimmu.2022.1057181.

References

Cui G, Yuan A, Goll R, Florholmen J . IL-17A in the tumor microenvironment of the human colorectal adenoma-carcinoma sequence. Scand J Gastroenterol. 2012; 47(11):1304-12. DOI: 10.3109/00365521.2012.725089. View

Cui G, Goll R, Olsen T, Steigen S, Husebekk A, Vonen B . Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. Cancer Immunol Immunother. 2006; 56(7):985-95. PMC: 11030272. DOI: 10.1007/s00262-006-0259-y. View

Cui G, Yuan A, Goll R, Olsen T, Husebekk A, Vonen B . Distinct changes of dendritic cell number and IL-12 mRNA level in adjacent mucosa throughout the colorectal adenoma-carcinoma sequence. Cancer Immunol Immunother. 2007; 56(12):1993-2001. PMC: 11030106. DOI: 10.1007/s00262-007-0345-9. View

Maywald R, Doerner S, Pastorelli L, De Salvo C, Benton S, Dawson E . IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci U S A. 2015; 112(19):E2487-96. PMC: 4434739. DOI: 10.1073/pnas.1422445112. View

Croci D, Zacarias Fluck M, Rico M, Matar P, Rabinovich G, Scharovsky O . Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother. 2007; 56(11):1687-700. PMC: 11030157. DOI: 10.1007/s00262-007-0343-y. View

Theoharides T, Zhang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A . IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci U S A. 2010; 107(9):4448-53. PMC: 2840132. DOI: 10.1073/pnas.1000803107. View

Zhang Y, Davis C, Shah S, Hughes D, Ryan J, Altomare D . IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis. Mol Carcinog. 2016; 56(1):272-287. PMC: 5630136. DOI: 10.1002/mc.22491. View

Schwartz S, Hernandez A, Evers B . The role of NF-kappaB/IkappaB proteins in cancer: implications for novel treatment strategies. Surg Oncol. 2000; 8(3):143-53. DOI: 10.1016/s0960-7404(00)00012-8. View

De la Fuente M, Macdonald T, Hermoso M . The IL-33/ST2 axis: Role in health and disease. Cytokine Growth Factor Rev. 2015; 26(6):615-23. DOI: 10.1016/j.cytogfr.2015.07.017. View

10.

Cui G, Qi H, Gundersen M, Yang H, Christiansen I, Sorbye S . Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol Immunother. 2014; 64(2):181-90. PMC: 11028541. DOI: 10.1007/s00262-014-1624-x. View

11.

Kuchler A, Pollheimer J, Balogh J, Sponheim J, Manley L, Sorensen D . Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol. 2008; 173(4):1229-42. PMC: 2543089. DOI: 10.2353/ajpath.2008.080014. View

12.

Cui J, Xu G, Liu J, Pang Z, Florholmen J, Cui G . The expression of non-mast histamine in tumor associated microvessels in human colorectal cancers. Pathol Oncol Res. 2012; 19(2):311-6. DOI: 10.1007/s12253-012-9584-y. View

13.

Cui G, Yuan A, Sun Z, Zheng W, Pang Z . IL-1β/IL-6 network in the tumor microenvironment of human colorectal cancer. Pathol Res Pract. 2018; 214(7):986-992. DOI: 10.1016/j.prp.2018.05.011. View

14.

Li Y, Shi J, Qi S, Zhang J, Peng D, Chen Z . IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE. J Exp Clin Cancer Res. 2018; 37(1):196. PMC: 6098640. DOI: 10.1186/s13046-018-0839-7. View

15.

Schiering C, Krausgruber T, Chomka A, Frohlich A, Adelmann K, Wohlfert E . The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014; 513(7519):564-568. PMC: 4339042. DOI: 10.1038/nature13577. View

16.

Chae W, Gibson T, Zelterman D, Hao L, Henegariu O, Bothwell A . Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci U S A. 2010; 107(12):5540-4. PMC: 2851824. DOI: 10.1073/pnas.0912675107. View

17.

Pohl M, Schmiegel W . Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow. Dig Dis. 2016; 34(5):574-9. DOI: 10.1159/000445267. View

18.

Csiszar A, Szentes T, Haraszti B, Balazs A, Petranyi G, Pocsik E . The pattern of cytokine gene expression in human colorectal carcinoma. Pathol Oncol Res. 2004; 10(2):109-16. DOI: 10.1007/BF02893465. View

19.

Contasta I, Berghella A, Pellegrini P, Adorno D . Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. Cancer Biother Radiopharm. 2003; 18(4):549-57. DOI: 10.1089/108497803322287628. View

20.

Hopkins M, Flanders W, Bostick R . Associations of circulating inflammatory biomarkers with risk factors for colorectal cancer in colorectal adenoma patients. Biomark Insights. 2012; 7:143-50. PMC: 3498968. DOI: 10.4137/BMI.S10092. View